drugset / Trial / NCT02399592

Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer

NCT02399592

Phase 2 Completed 23 enrolled Vejle Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to to investigate the effect of tocotrienol as a nutritional supplement in combination with bevacizumab in patients with advanced ovarian cancer.

Timeline

Start
2015-03
Primary completion
2019-07
Completion
2019-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocotrienol Small molecule 300 mg
Background Bevacizumab Monoclonal antibody 10 mg/kg

Indications